Follistatin-344 gene therapy built muscle in mice and macaques

Does follistatin-344 build muscle?

Follistatin-344 builds muscle in animals when a virus delivers its gene into muscle tissue ^[1]⁠^[2]. No study has tested whether injected recombinant FS-344 peptide does the same in humans.

A single intramuscular injection of AAV1-FS344 in normal and dystrophic mice produced the largest and most sustained gains in muscle mass and strength among all myostatin inhibitors tested. The effects persisted more than two years, with no detected adverse organ or reproductive effects ^[1].

The result extended to cynomolgus macaques. Intramuscular AAV1-FS344 injected into the quadriceps produced pronounced, durable increases in muscle size and strength, with no abnormal organ morphology or function on follow-up ^[2].

Both are well-designed studies, and both tested the same thing: muscle tissue genetically reprogrammed to manufacture its own FS-344 continuously, for years, from a single dose. Neither tests what happens when a person injects synthetic FS-344 peptide subcutaneously every other day.

What human trials of follistatin-344 exist?

Two Phase 1/2a open-label gene therapy trials, with six patients each, make up the human record ^[4]⁠^[5]. Both used AAV-mediated gene delivery rather than recombinant protein.

In six Becker muscular dystrophy patients, bilateral intramuscular AAV1.CMV.FS344 produced six-minute walk test improvements of 29 to 125 meters in four of the six subjects. The trial reported no adverse events, and biopsies showed reduced fibrosis and increased fiber size at higher doses ^[4].

In six patients with sporadic inclusion body myositis, the same gene therapy approach improved six-minute walk distance by a median of 56.0 meters per year, against a 25.8-meter annual decline in matched untreated controls (p = 0.01). Histology again showed reduced fibrosis ^[5].

Both are encouraging, carefully monitored results in specific disease populations. Both are also small, open-label, and uncontrolled in the randomized sense.

No randomized controlled trial of any follistatin-344 formulation exists. No published pharmacokinetic or safety study of recombinant FS-344 protein, injected by any route, in any population, has been conducted. That gap is what the D, limited evidence grade describes: a deep and real preclinical mechanism, with near-zero translation to the product form people use.

Why does gene therapy not predict what an injection does?

Viral gene transfer makes muscle fibers produce FS-344 continuously for years, while an injected peptide is metabolized and cleared like any other exogenous protein. The two delivery methods have essentially nothing in common pharmacologically.

A protein injected as a bolus faces degradation and clearance dynamics entirely different from a transgene product manufactured inside muscle fibers. No bridging study has tested whether the gene-therapy results carry over to a subcutaneous injection.

How does follistatin-344 work?

Follistatin is an endogenous glycoprotein that binds and neutralizes ligands in the TGF-beta superfamily, most notably myostatin (GDF-8) and activin A. Myostatin normally acts as a brake on skeletal muscle growth, and sequestering it releases that brake. That release is the biological basis for every muscle-growth claim attached to the molecule.

"Blocks myostatin" oversimplifies it. Follistatin is not myostatin-selective. Activin A shares receptor machinery with myostatin and does independent work regulating follicle-stimulating hormone (FSH) secretion, wound healing, and tissue fibrosis. Neutralizing follistatin's target list means neutralizing activin A too, whether or not that is the intended effect ^[3]. Growth hormone's split between body composition and strength shows why added muscle size and usable function are measured separately.

What is the difference between FS-344 and FS-315?

FS-344 and FS-315 are different follistatin isoforms, and they differ in how the protein distributes through tissue and how long it persists.

That difference is why the gene-therapy programs chose FS-344. Researchers wanted an isoform that could act locally in injected muscle rather than get soaked up systemically before reaching target tissue ^[3].

The distinction is a real and important pharmacological one, and it was established in the context of AAV-delivered gene therapy, where FS-344 is continuously synthesized inside the injected muscle. Whether the same local-versus-systemic behavior holds for a bolus of recombinant FS-344 protein injected subcutaneously has not been studied.

Where do the follistatin-344 dosing protocols come from?

The 100 to 300 mcg per day protocols come from repetition on forums, not from a dose-response study. They typically run for four to six weeks, and no published study of injected FS-344 peptide in humans exists for them to derive from.

Without human pharmacokinetic data, the peptide's half-life after subcutaneous or intramuscular injection is unknown. So is how much reaches muscle tissue intact, and whether repeated dosing at any level reproduces even a fraction of what continuous local expression from gene therapy achieves.

The numbers circulating online are consensus by repetition, not derived quantities. PEG-MGF's protocols rest on the same kind of untested figure, and what peptide dosing research tests covers how often protocol rules turn out to be extrapolations.

What are the real risks of follistatin-344?

The most mechanistically grounded concern is activin A inhibition's effect on the hypothalamic-pituitary-gonadal axis. Activin A has an established role stimulating FSH secretion, and suppressing it plausibly interferes with that regulation. No study measured this with injected recombinant peptide, so its magnitude in that setting is unknown.

That concern is more defensible than the diffuse "tumor risk" narrative on forums, which draws on TGF-beta superfamily biology being complex and growth-related rather than on a specific finding. The two human gene-therapy trials reported no adverse events over their observation windows, and six-person studies with short follow-up cannot rule out rare or long-latency effects ^[4]⁠^[5].

Concerns about chronic myostatin or activin suppression affecting tendon or cardiac tissue appear in broader animal literature. They are plausible extrapolation, not established finding.

Sourcing is the more immediate practical problem. Field testing of vials sold as FS-344 has reportedly found many containing no detectable follistatin protein at all. For many buyers, the biological risk profile is moot because no active compound is present. How to read a peptide COA covers what a vendor's own test document does and does not establish.

What has never been measured for injected FS-344?

Nearly everything about follistatin-344 as people use it is uncharacterized:

• Pharmacokinetics. Human pharmacokinetics of injected recombinant FS-344 are unmeasured.
• Dose. No dose-response relationship has been established.
• Bioavailability. How much of a subcutaneous dose reaches muscle intact is unknown.
• Hormone axis. Effects on the reproductive hormone axis in a non-disease population have not been studied.
• Long-term safety. Repeated self-administered dosing has no safety record.
• Distribution. Whether the local-versus-systemic behavior seen with gene-therapy-expressed FS-344 applies to an injected protein bolus has not been tested.

Until that work exists, every specific protocol in circulation is extrapolation from a molecule tested a different way, in a different context, for a different purpose.